Select Language
Free Registration

CD163

CD163 Overview

English NameScavenger receptor cysteine-rich type 1 protein M130Approved Drugs1
Drugs in Clinical Trials1Target SynonymCD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Highest Development StageApproved
English NameScavenger receptor cysteine-rich type 1 protein M130
Target SynonymCD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Approved Drugs1
Drugs in Clinical Trials1
Highest Development StageApproved

CD163 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
CD3-H52E8
Human
HEK293
Human CD163 Protein, His Tag
Total: 1
  • 1

CD163 Background

Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

CD163 Synonyms

CD163,M130

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OR-2805OR-2805Phase 2 ClinicalOncoResponse IncCarcinoma, Non-Small-Cell Lung; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
TetrachlorodecaoxideOXO-K993; WF-10; TCDOApprovedNuvox Pharma LLCOxoferin, Immunokine, WF10ThailandInflammation; Rhinitis, Allergicnull1997-01-01Diabetic Foot; HIV Infections; Inflammation; Rhinitis, Allergic
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland